BRCA1, BRCA2, TP53, and CDKN2A germline mutations in patients with breast cancer and cutaneous melanoma
- PMID: 17624602
- DOI: 10.1007/s10689-007-9143-y
BRCA1, BRCA2, TP53, and CDKN2A germline mutations in patients with breast cancer and cutaneous melanoma
Abstract
Purpose: From epidemiological studies it appears that breast cancer (BC) and cutaneous melanoma (CMM) in the same individual occur at a higher frequency than expected by chance. Genetic factors common to both cancers can be suspected. Our goal was to estimate the involvement of "high risk" genes in patients presenting these two neoplasia, selected irrespectively from family history and age at diagnosis.
Experimental design: Eighty two patients with BC and CMM were screened for BRCA1, BRCA2, TP53, CDKN2A and CDK4 (exon 2) germline mutations.
Results: Deleterious mutations were identified in 6 patients: two carriers of a BRCA1 germline mutation, two carriers of TP53 germline mutations (one of which also harbored a BRCA2 deleterious mutation, the other one a BRCA2 unclassified variant), and two carriers of a CDKN2A germline mutation. In addition, 6 variants of unknown signification were identified in BRCA1 or BRCA2 genes. Regarding family history, 3/13 (23%) patients with a positive family history of BC or CMM were carriers of a germline mutation, whereas only 3/69 (4%) patients without family history were carriers of a germline mutation.
Conclusion: Our findings show that few patients with BC and CMM who lacked family histories of these cancers are carriers of deleterious germline mutations in four of the five genes we examined. We describe for the first time, two simultaneous BRCA2 and TP53 mutations, suggesting that analysis in more than one gene could be performed if a patient's personal or familial history does not match a single syndrome.
Similar articles
-
Contribution of CDKN2A/P16 ( INK4A ), P14 (ARF), CDK4 and BRCA1/2 germline mutations in individuals with suspected genetic predisposition to uveal melanoma.Fam Cancer. 2010 Dec;9(4):663-7. doi: 10.1007/s10689-010-9379-9. Fam Cancer. 2010. PMID: 20842456
-
Comparable frequency of BRCA1, BRCA2 and TP53 germline mutations in a multi-ethnic Asian cohort suggests TP53 screening should be offered together with BRCA1/2 screening to early-onset breast cancer patients.Breast Cancer Res. 2012 Apr 16;14(2):R66. doi: 10.1186/bcr3172. Breast Cancer Res. 2012. PMID: 22507745 Free PMC article.
-
Comprehensive analysis of BRCA1, BRCA2 and TP53 germline mutation and tumor characterization: a portrait of early-onset breast cancer in Brazil.PLoS One. 2013;8(3):e57581. doi: 10.1371/journal.pone.0057581. Epub 2013 Mar 1. PLoS One. 2013. PMID: 23469205 Free PMC article.
-
Hereditary breast cancer; Genetic penetrance and current status with BRCA.J Cell Physiol. 2019 May;234(5):5741-5750. doi: 10.1002/jcp.27464. Epub 2018 Dec 14. J Cell Physiol. 2019. PMID: 30552672 Review.
-
Current review of TP53 pathogenic germline variants in breast cancer patients outside Li-Fraumeni syndrome.Hum Mutat. 2018 Dec;39(12):1764-1773. doi: 10.1002/humu.23656. Epub 2018 Oct 3. Hum Mutat. 2018. PMID: 30240537 Review.
Cited by
-
p16 overexpression and 9p21 deletion are linked to unfavorable tumor phenotype in breast cancer.Oncotarget. 2016 Dec 6;7(49):81322-81331. doi: 10.18632/oncotarget.13227. Oncotarget. 2016. PMID: 27835607 Free PMC article.
-
BRCA1/2 mutations are not a common cause of malignant melanoma in the Polish population.PLoS One. 2018 Oct 4;13(10):e0204768. doi: 10.1371/journal.pone.0204768. eCollection 2018. PLoS One. 2018. PMID: 30286154 Free PMC article.
-
Two cancers in one: breast carcinoma with underlying melanoma.Proc (Bayl Univ Med Cent). 2017 Jul;30(3):316-318. doi: 10.1080/08998280.2017.11929630. Proc (Bayl Univ Med Cent). 2017. PMID: 28670070 Free PMC article.
-
Germline mutations in candidate predisposition genes in individuals with cutaneous melanoma and at least two independent additional primary cancers.PLoS One. 2018 Apr 11;13(4):e0194098. doi: 10.1371/journal.pone.0194098. eCollection 2018. PLoS One. 2018. PMID: 29641532 Free PMC article.
-
CDKN2A germline alterations and the relevance of genotype-phenotype associations in cancer predisposition.Hered Cancer Clin Pract. 2021 Mar 25;19(1):21. doi: 10.1186/s13053-021-00178-x. Hered Cancer Clin Pract. 2021. PMID: 33766116 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous